CD158 receptor controls cytotoxic T-lymphocyte susceptibility to tumor-mediated activation-induced cell death by interfering with Fas signaling

Cancer Res. 2003 Nov 1;63(21):7475-82.

Abstract

Renal cell carcinoma-infiltrating lymphocytes express killer cell immunoglobulin-like receptors (KIRs) that inhibit antitumor CD8+ T-cell functions and may contribute to local self-tolerance. In the present study, to better examine the functional consequences of KIR engagement on CTL-tumor interactions, we investigated the influence of KIR2DL1/CD158a on CTL survival. We show that both KIR+ and KIR- antigen-specific CTLs express Fas and Fas ligand and were susceptible to activation-induced cell death (AICD) triggered by coated anti-CD3 monoclonal antibodies. In KIR+ CTLs, anti-CD158a monoclonal antibodies partially inhibited anti-CD3-induced AICD. Interestingly, T-cell receptor activation by cognate tumor cells induced apoptosis in KIR+ CTLs but not in KIR- CTLs. In addition, co-engagement of T-cell receptors and KIRs by tumor cells decreased tumor-mediated CTL apoptosis. Blocking the interaction of KIR/HLA-Cw4 resulted in the restoration of tumor-induced AICD. Most importantly, our data indicate that KIR engagement affected two proximal events of Fas signaling pathway, a sustained c-FLIP-L induction and a decrease in caspase 8 activity. These studies provide evidence that tumor cells selectively favor the local persistence of nonfunctional KIR+ CTLs by promoting their survival.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / immunology
  • Antibody Specificity
  • CD3 Complex / immunology
  • Carcinoma, Renal Cell / immunology
  • Cell Death / immunology
  • Down-Regulation
  • Humans
  • Kidney Neoplasms / immunology
  • Lymphocyte Activation
  • Receptors, Immunologic / immunology*
  • Receptors, KIR
  • Receptors, KIR2DL1
  • Signal Transduction / immunology
  • T-Lymphocytes, Cytotoxic / immunology*
  • Tumor Cells, Cultured
  • fas Receptor / immunology*

Substances

  • Antibodies, Monoclonal
  • CD3 Complex
  • Receptors, Immunologic
  • Receptors, KIR
  • Receptors, KIR2DL1
  • fas Receptor